NASDAQ:XLO Xilio Therapeutics - XLO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.65 -0.32 (-8.06%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.50▼$4.0750-Day Range$1.97▼$4.2852-Week Range$1.95▼$14.86Volume144,612 shsAverage Volume97,423 shsMarket Capitalization$100.27 millionP/E RatioN/ADividend YieldN/APrice Target$11.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Xilio Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside208.2% Upside$11.25 Price TargetShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.12) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector185th out of 1,055 stocksPharmaceutical Preparations Industry86th out of 518 stocks 3.5 Analyst's Opinion Consensus RatingXilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.25, Xilio Therapeutics has a forecasted upside of 208.2% from its current price of $3.65.Amount of Analyst CoverageXilio Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.19% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 31.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XLO. Previous Next 2.6 News and Social Media Coverage News SentimentXilio Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for XLO on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions60.46% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($3.12) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xilio Therapeutics (NASDAQ:XLO) StockXilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address XLO Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comXilio Therapeutics (NASDAQ:XLO) Price Target Cut to $10.00 by Analysts at Morgan StanleyJanuary 28, 2023 | americanbankingnews.comXilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Drop in Short InterestJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 26, 2023 | finance.yahoo.comInstitutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the mostJanuary 25, 2023 | seekingalpha.comXLO Xilio Therapeutics, Inc.January 25, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Are on Track for Massive Gains, Say AnalystsNovember 23, 2022 | finance.yahoo.comXilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12November 9, 2022 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial ResultsJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…September 23, 2022 | finance.yahoo.comXilio Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 6, 2022 | finance.yahoo.comXilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 11, 2022 | seekingalpha.comXilio Therapeutics GAAP EPS of -$0.90August 11, 2022 | finance.yahoo.comIs Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth?August 9, 2022 | finance.yahoo.comXilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial ResultsAugust 7, 2022 | finance.yahoo.comXilio Therapeutics, Inc. (XLO)June 16, 2022 | finance.yahoo.comXilio Therapeutics Announces Promotion of Martin Huber, M.D., to PresidentMay 18, 2022 | finance.yahoo.comXilio Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceMay 17, 2022 | finance.yahoo.comXilio Therapeutics Appoints Stacey Davis as Chief Business OfficerMay 12, 2022 | investing.comXilio Therapeutics Reports Pipeline and Business HighlightsMay 12, 2022 | finance.yahoo.comXilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial ResultsApril 7, 2022 | finance.yahoo.comXilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceMarch 1, 2022 | seekingalpha.comXilio Therapeutics GAAP EPS of -$0.98 misses by $0.06March 1, 2022 | finance.yahoo.comXilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial ResultsFebruary 28, 2022 | finance.yahoo.comXilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare ConferenceFebruary 7, 2022 | finance.yahoo.comRiverVest Venture Management LLC Buys Xilio Therapeutics IncFebruary 3, 2022 | finance.yahoo.comXilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology DayJanuary 25, 2022 | finance.yahoo.comAre Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address XLO Company Calendar Last Earnings11/09/2022Today1/31/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees74Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.25 High Stock Price Forecast$15.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+208.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.95% Return on Assets-45.58% Debt Debt-to-Equity Ratio0.04 Current Ratio8.45 Quick Ratio8.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.95 per share Price / Book0.53Miscellaneous Outstanding Shares27,470,000Free Float26,510,000Market Cap$100.27 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Rene Russo BCPS (Age 48)Pharm.D, Pharm.D., CEO & Director Comp: $873.8kDr. Martin H. Huber M.D. (Age 62)Pres and Head of R&D Comp: $739.46kMr. Edward C. English (Age 56)VP of Fin. & Accounting, Treasury and Principal Accounting Officer Dr. Uli Bialucha Ph.D.Chief Scientific OfficerMr. Christopher FrankenfieldChief Legal & Admin. OfficerJulissa VianaVP of Corp. CommunicationsMr. Bill Avery Ph.D.Sr. VP of Nonclinical Devel.Ms. Stacey J. DavisChief Bus. OfficerMore ExecutivesKey CompetitorsViveon Health AcquisitionNYSE:VHAQOpiant PharmaceuticalsNASDAQ:OPNTVaccitechNASDAQ:VACCPardes BiosciencesNASDAQ:PRDSAtossa TherapeuticsNASDAQ:ATOSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 472,368 shares on 11/15/2022Ownership: 3.245%Renaissance Technologies LLCSold 46,800 shares on 11/14/2022Ownership: 0.104%Ergoteles LLCSold 4,607 shares on 11/14/2022Ownership: 0.047%View All Institutional Transactions XLO Stock - Frequently Asked Questions Should I buy or sell Xilio Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares. View XLO analyst ratings or view top-rated stocks. What is Xilio Therapeutics' stock price forecast for 2023? 3 brokerages have issued 12 month price objectives for Xilio Therapeutics' shares. Their XLO share price forecasts range from $7.00 to $15.00. On average, they expect the company's share price to reach $11.25 in the next year. This suggests a possible upside of 183.4% from the stock's current price. View analysts price targets for XLO or view top-rated stocks among Wall Street analysts. How have XLO shares performed in 2023? Xilio Therapeutics' stock was trading at $2.69 on January 1st, 2023. Since then, XLO shares have increased by 47.6% and is now trading at $3.97. View the best growth stocks for 2023 here. Are investors shorting Xilio Therapeutics? Xilio Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 19,200 shares, a decline of 31.4% from the December 31st total of 28,000 shares. Based on an average trading volume of 35,800 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are sold short. View Xilio Therapeutics' Short Interest. When is Xilio Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our XLO earnings forecast. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) released its earnings results on Wednesday, November, 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.17. When did Xilio Therapeutics IPO? (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share. What is Xilio Therapeutics' stock symbol? Xilio Therapeutics trades on the NASDAQ under the ticker symbol "XLO." How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xilio Therapeutics' stock price today? One share of XLO stock can currently be purchased for approximately $3.97. How much money does Xilio Therapeutics make? Xilio Therapeutics (NASDAQ:XLO) has a market capitalization of $109.06 million. The company earns $-75,800,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis. How can I contact Xilio Therapeutics? The official website for the company is www.xiliotx.com. The company can be reached via phone at 857-524-2466 or via email at monique@thrustsc.com. This page (NASDAQ:XLO) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.